A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed

Sponsor
Genentech, Inc.
Study ID
NCT00097019
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, single-arm, two-stage, multicenter Phase II study evaluating the efficacy and safety of bevacizumab in women with platinum resistant, advanced (Stage III or IV) EOC (epithelial ovarian cancer) or PPC (primary peritoneal cancer) that subsequently progressed either during treatment with Doxil or Hycamtin therapy or within 3 months of discontinuing treatment with Doxil or Hycamtin therapy.

Key Dates

First listed
Nov 18, 2004
Start date
Feb 28, 2005
Status verified
May 2017
Primary completion
May 31, 2006
Completion
May 31, 2006

Study Design

Enrollment
53 participants
Primary purpose
TREATMENT

Related Studies